These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36115256)

  • 1. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
    Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
    Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
    Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
    Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
    Bhayana S; Booth GL; Asa SL; Kovacs K; Ezzat S
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6290-5. PubMed ID: 16118335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
    Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
    Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
    Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
    Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE.
    Ezzat S; Caspar-Bell GM; Chik CL; Denis MC; Domingue MÈ; Imran SA; Johnson MD; Lochnan HA; Grégoire Nyomba BL; Prebtani A; Ridout R; Ramirez JAR; Van Uum S
    Endocr Pract; 2019 Apr; 25(4):379-393. PubMed ID: 30657362
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
    Petersenn S; Houchard A; Sert C; Caron PJ;
    Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
    Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
    Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].
    Jaquet P; Cortet-Rudelli Ch; Sassolas G; Morange-Ramos I; Chanson P; Brue T; Andrieu JM; Beckers A; Bertherat J; Borson-Chazot F; Brassier G; Caron P; Cogne M; Cottier JP; Delemer B; Dufour H; Enjalbert A; Figarella-Branger D; Gaillard R; Gueydan M; Jan M; Kuhn JM; Raingeard I; Regis J; Roger P; Rohmer V; Sadoul JL; Saveanu A; Tabarin A; Travers N; Trouillas J;
    Ann Endocrinol (Paris); 2003 Dec; 64(6):434-41. PubMed ID: 15067248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
    Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
    J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
    Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
    Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
    Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
    Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC;
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):375-81. PubMed ID: 15009004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
    Schwyzer L; Starke RM; Jane JA; Oldfield EH
    J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.